Do Youn Oh

Summary

Affiliation: Seoul National University
Country: Korea

Publications

  1. ncbi Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer
    Sun Kyung Baek
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    BMC Gastroenterol 11:56. 2011
  2. ncbi Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection
    Yun Gyoo Lee
    Department of Internal Medicine, Seoul National University Hospital, and Cancer Research Institute, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence, Seoul National University College of Medicine, Seoul, Republic of Korea
    BMC Cancer 11:188. 2011
  3. ncbi The role of PET/CT in detection of gastric cancer recurrence
    Sung Hoon Sim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 9:73. 2009
  4. ncbi Artificial nutrition and hydration in terminal cancer patients: the real and the ideal
    Do Youn Oh
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, South Korea
    Support Care Cancer 15:631-6. 2007
  5. ncbi A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
    Do Youn Oh
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, 110 744, Korea
    Cancer Chemother Pharmacol 65:527-36. 2010
  6. ncbi Antibiotic use during the last days of life in cancer patients
    D Y Oh
    Seoul National University Boramae Hospital, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Eur J Cancer Care (Engl) 15:74-9. 2006
  7. ncbi CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience
    Do Youn Oh
    Seoul National University Boramae Hospital, 425 Shindaebang dong, Dongjak Gu, 156 707, Seoul, South Korea
    Support Care Cancer 14:103-8. 2006
  8. ncbi Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 7:63. 2007
  9. ncbi Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung)
    Su Jung Kim
    Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
    Am J Clin Oncol 35:549-56. 2012
  10. ncbi Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis
    Junshik Hong
    Department of Internal Medicine, Seoul National University Hospital, 101 Daehang ro, Jongno gu, Seoul, Korea
    Cancer Chemother Pharmacol 67:1323-31. 2011

Collaborators

Detail Information

Publications103 found, 100 shown here

  1. ncbi Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer
    Sun Kyung Baek
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    BMC Gastroenterol 11:56. 2011
    ..In this study, we performed an evaluation of clinicopathologic characteristics, treatment outcome, and prognosis in patients with gastric HAC...
  2. ncbi Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection
    Yun Gyoo Lee
    Department of Internal Medicine, Seoul National University Hospital, and Cancer Research Institute, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence, Seoul National University College of Medicine, Seoul, Republic of Korea
    BMC Cancer 11:188. 2011
    ..This study is to determine the clinical role of 18F-FDG PET/CT during post-operative surveillance of suspected recurrent BTC based on symptoms, laboratory findings and contrast-enhanced CT (ceCT) findings...
  3. ncbi The role of PET/CT in detection of gastric cancer recurrence
    Sung Hoon Sim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 9:73. 2009
    ..The purpose of this study is to evaluate the efficacy and usefulness of PET/CT for detecting recurrence of gastric cancer after curative resection...
  4. ncbi Artificial nutrition and hydration in terminal cancer patients: the real and the ideal
    Do Youn Oh
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, South Korea
    Support Care Cancer 15:631-6. 2007
    ..Administered calories and changes in these according to time and "DNR" (do-not-resuscitate) status were noted...
  5. ncbi A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
    Do Youn Oh
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, 110 744, Korea
    Cancer Chemother Pharmacol 65:527-36. 2010
    ..To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer...
  6. ncbi Antibiotic use during the last days of life in cancer patients
    D Y Oh
    Seoul National University Boramae Hospital, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Eur J Cancer Care (Engl) 15:74-9. 2006
    ..But symptomatic improvement was not achieved in more than half of the patients. Further study should be undertaken to clarify the benefit of antibiotics in terminal stage cancer patients...
  7. ncbi CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience
    Do Youn Oh
    Seoul National University Boramae Hospital, 425 Shindaebang dong, Dongjak Gu, 156 707, Seoul, South Korea
    Support Care Cancer 14:103-8. 2006
    ..We conducted this prospective observational study to characterize current CPR and do-not-resuscitate (DNR) practice among terminal cancer patients in South Korea...
  8. ncbi Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 7:63. 2007
    ....
  9. ncbi Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung)
    Su Jung Kim
    Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
    Am J Clin Oncol 35:549-56. 2012
    ..Neuroendocrine tumor originates from several sites. This study was conducted to reveal the differences in clinical course of neuroendocrine tumors by the origin...
  10. ncbi Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis
    Junshik Hong
    Department of Internal Medicine, Seoul National University Hospital, 101 Daehang ro, Jongno gu, Seoul, Korea
    Cancer Chemother Pharmacol 67:1323-31. 2011
    ..To evaluate the efficacy and safety of S-1 in combination with oxaliplatin in a biweekly schedule as first-line treatment in metastatic colorectal cancer and the association between genetic polymorphisms and treatment outcomes...
  11. ncbi Epidermal growth factor receptor intron 1 CA dinucleotide repeat polymorphism and survival of advanced gastric cancer patients treated with cetuximab plus modified FOLFOX6
    Sae Won Han
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    Cancer Sci 101:793-9. 2010
    ..These results suggest that the EGFR intron 1 CA repeat polymorphism could be a useful, predictive biomarker of cetuximab efficacy in AGC and merits further investigation in randomized studies...
  12. ncbi Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience
    Kyubo Kim
    Departments of Radiation Oncology, Seoul National University College of Medicine, Republic of Korea
    Am J Clin Oncol 35:136-40. 2012
    ..To analyze the outcome of adjuvant chemoradiotherapy for patients with extrahepatic bile duct (EHBD) cancer, and to identify the prognostic factors for these patients...
  13. ncbi Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients
    Sae Won Han
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Republic of Korea
    Lung Cancer 54:201-7. 2006
    ..Direct comparison between clinical predictors and EGFR mutation for their predictive power has not been reported...
  14. ncbi ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy
    Ji Won Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Korea
    Oncology 83:218-27. 2012
    ..The aim of this study was to elucidate clinical implications of ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer (MBC) after taxane plus trastuzumab (TH) chemotherapy...
  15. ncbi Increasing nodal ratio is a poor prognostic factor for survival in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study
    Jin Soo Kim
    Department of Internal Medicine, Seoul National University Hospital, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Republic of Korea
    Jpn J Clin Oncol 41:245-52. 2011
    ..The aim of this study is to evaluate the efficacy of adjuvant chemotherapy with 5-fluorouracil and cisplatin in gastric cancer patients and to assess prognostic factors affecting relapse and survival...
  16. ncbi The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer
    Jong Mu Sun
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
    Lung Cancer 68:427-32. 2010
    ..We sought to identify the relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer (NSCLC)...
  17. ncbi Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells
    Hwang Phill Kim
    Cancer Research Institute, Seoul National University College of Medicine, Chongno Gu, Seoul, Korea
    Mol Cancer Ther 7:607-15. 2008
    ....
  18. ncbi Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy
    Hye Suk Han
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    J Korean Med Sci 24:910-7. 2009
    ..Furthermore, the magnitude of HER2 amplification is an independent predictive factor of TTP...
  19. ncbi Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer?
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Int J Radiat Oncol Biol Phys 77:1186-90. 2010
    ..To analyze the outcome of adjuvant chemoradiotherapy for patients with distal common bile duct (CBD) cancer who underwent curative surgery, and to identify the prognostic factors for these patients...
  20. ncbi Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience
    Kyubo Kim
    Departments of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Am J Clin Oncol 35:533-6. 2012
    ..To compare the treatment outcome of surgery alone with that of surgery followed by adjuvant chemoradiotherapy (CRT) for duodenal cancer...
  21. ncbi Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
    BMC Cancer 8:148. 2008
    ..We also analyzed the predictive or prognostic value of germline polymorphisms of candidate genes associated with 5-FU and oxaliplatin...
  22. ncbi Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
    J Korean Med Sci 25:235-9. 2010
    ..A bcl-2(-)/ER(-) phenotype and p53 expression are useful molecular markers predicting loco-regional relapse-free and distant metastasis-free survival, respectively, in patients treated with breast conserving surgery and radiotherapy...
  23. ncbi The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use
    Youngil Koh
    Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, 101 Daehangro, Chongno Gu, Seoul 110 744, Republic of Korea
    Jpn J Clin Oncol 42:1020-7. 2012
    ..We also investigated the clinical applicability of Choi's criteria to Korean gastrointestinal stromal tumor patients undergoing imatinib therapy...
  24. ncbi Distant metastasis risk stratification for patients undergoing curative resection followed by adjuvant chemoradiation for extrahepatic bile duct cancer
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Int J Radiat Oncol Biol Phys 84:81-7. 2012
    ..To analyze the prognostic factors predicting distant metastasis in patients undergoing adjuvant chemoradiation for extrahepatic bile duct (EHBD) cancer...
  25. ncbi Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy
    Ji Won Kim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    Am J Clin Oncol 34:125-9. 2011
    ..The objectives of this analysis were to investigate efficacy and safety of sorafenib in these patients and to elucidate risk factors associated with clinical outcomes...
  26. ncbi Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak Ro, Jongno gu, Seoul 110 744, Republic of Korea
    Clin Transl Oncol 14:391-5. 2012
    ..To analyse the outcome of adjuvant chemoradiotherapy for periampullary adenocarcinoma and the impact of tumour location as a prognosticator...
  27. ncbi The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen
    Jin Won Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University, Seoul, Korea
    Anticancer Res 32:1547-53. 2012
    ..We aimed to clarify the prognostic significance of HER2 positivity in advanced gastric cancer...
  28. ncbi Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
    Mi Jung Kim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 8:374. 2008
    ..Fluoropyrimidine or gemcitabine, with or without platinum, are most frequently used. We conducted this study to clarify the efficacy of palliative chemotherapy in BTC...
  29. ncbi Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer
    Sae Won Han
    Department of Internal Medicine, Seoul National University Hospital and Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Korea
    Pharmacogenet Genomics 17:313-9. 2007
    ..Therefore, CA repeat polymorphism in intron 1 was analyzed for its association with gefitinib responsiveness together with epidermal growth factor receptor mutation in Korean patients...
  30. ncbi Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Tumori 97:280-5. 2011
    ..To compare the outcome of concurrent versus sequential administration of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer...
  31. ncbi The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines
    Hyun Jin Nam
    Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
    Invest New Drugs 30:2148-60. 2012
    ..Our results support the need for further study of PF00299804 alone or combined with gemcitabine for the treatment of BTC...
  32. ncbi Prognostic factors affecting the outcome of salvage radiotherapy for isolated locoregional recurrence after mastectomy
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
    Am J Clin Oncol 33:23-7. 2010
    ..To evaluate the prognostic factors affecting the outcome of salvage radiotherapy for isolated locoregional recurrence after mastectomy...
  33. ncbi Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehang ro, Jongno gu, Seoul, 110 744, Korea
    Breast Cancer Res 13:R22. 2011
    ..The purpose of this study was to identify the predictive or prognostic value of Ki-67 among patients with TNBC treated with neoadjuvant chemotherapy, and the role of Ki-67 in further classification of TNBC...
  34. ncbi RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    Cancer Lett 299:22-8. 2010
    ..In conclusion, RAD001 showed growth inhibitory activity against gastric cancer cells and acted synergistically with cytotoxic agents such as 5-FU by downregulating TS...
  35. ncbi Aggressiveness of cancer-care near the end-of-life in Korea
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Republic of Korea
    Jpn J Clin Oncol 38:381-6. 2008
    ..The aim of this study was to examine the appropriateness of chemotherapy and care in Korean cancer patients near the end-of-life...
  36. ncbi Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab
    Hye Jung Chang
    Department of Internal Medicine, Seoul National University Hospital, 28 Yongon Dong, Chongno Gu, Seoul 110 744, South Korea
    Jpn J Clin Oncol 41:593-9. 2011
    ..Recent studies have shown that the human epidermal growth factor receptor 2 status of a metastatic site may differ from that of the primary site. This difference may influence patient prognosis and response to therapy...
  37. ncbi Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
    Sae Won Han
    Department of Internal Medicine, Seoul National University Hospital, Seoul, 110 744 Korea
    J Clin Oncol 23:2493-501. 2005
    ..This study was undertaken to investigate the effects of epidermal growth factor receptor (EGFR) mutation and its downstream signaling on response and survival in non-small-cell lung cancer (NSCLC) patients treated with gefitinib...
  38. ncbi A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research
    Do Youn Oh
    Department of Internal Medicine, Seoul National University Hospital, 28 Yongondong, Chongno Gu, Seoul, 110 744, Korea
    Invest New Drugs 30:1164-74. 2012
    ..To confirm the efficacy and toxicity of Erlotinib in combination with Gemcitabine and Capecitabine when used as a first-line therapy in metastatic/recurrent pancreatic cancer (PC)...
  39. ncbi Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehangno, Jongno gu, Seoul 110 744, Republic of Korea
    Jpn J Clin Oncol 39:111-5. 2009
    ..The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy...
  40. ncbi Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer
    Youngil Koh
    Departments of Internal Medicine and daggerPathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
    J Thorac Oncol 5:320-5. 2010
    ..We analyzed the significance of class III beta-tubulin (TUBB3) expression in curatively resected non-small cell lung cancer as a prognostic marker along with previously reported excision repair cross complementation group 1 (ERCC1)...
  41. ncbi Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer
    In Sil Choi
    Department of Internal Medicine, Seoul National University College of Medicine, Chongno Gu, Seoul 110 744, Korea
    Jpn J Clin Oncol 35:6-12. 2005
    ..The objectives of the present study were to assess the efficacy and tolerability of perioperative paclitaxel/platinum-based chemotherapy and surgery in patients with stage IIIA clinical N2 (cN2) non-small cell lung cancer (NSCLC)...
  42. ncbi DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells
    Heesun Kim
    Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
    Int J Oncol 36:1563-72. 2010
    ..This study is the first to show that DNMT3L exerts a major effect on the transcriptional regulation of a specific target gene, such as TDG, despite the absence of enzymatic activity...
  43. ncbi Prognostic factors for recurrent breast cancer patients with an isolated, limited number of lung metastases and implications for pulmonary metastasectomy
    Ho Young Yhim
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    Cancer 116:2890-901. 2010
    ..The aim of this study was to evaluate the clinical treatment outcomes of recurrent breast cancer with a limited number of isolated lung metastases, and to evaluate the role of pulmonary metastasectomy...
  44. ncbi The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
    Jin Won Kim
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Republic of Korea
    Cancer Lett 272:296-306. 2008
    ..These results provide a rationale for the future clinical trials of lapatinib combined with cytotoxic drugs in the treatment of HER2-positive gastric cancer...
  45. ncbi Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting
    Kyu Hyoung Lim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, 110 744, Korea
    Cancer Chemother Pharmacol 68:1017-26. 2011
    ....
  46. ncbi ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University Hospital, Republic of Korea
    Lung Cancer 60:401-7. 2008
    ..30% in ERCC1-negative tumors, P=0.014). In conclusion, ERCC1 expression was identified as a positive prognostic marker in resected NSCLC. In addition, EGFR mutations were more frequently found in ERCC1-negative tumors...
  47. ncbi Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer
    Kyu Hyoung Lim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    Oncology 83:57-66. 2012
    ..The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) as salvage chemotherapy in biliary tract cancer (BTC) and to identify prognostic factors...
  48. ncbi Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
    Su Jung Kim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
    BMC Cancer 10:448. 2010
    ..Studies about the biology, treatment pattern, and treatment outcome of metastatic/recurrent neuroendocrine tumor (NET) have been few...
  49. ncbi Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer
    Jinah Park
    Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    Invest New Drugs 30:1404-12. 2012
    ..This demonstrates the potential for P-cadherin to be used as a target for treatment of gastric cancer...
  50. ncbi Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer
    Hyun Jin Nam
    Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Jongno gu, Seoul, 110 744, Korea
    Mol Cancer Ther 11:439-51. 2012
    ....
  51. ncbi Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
    Hee Jun Kim
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Korea
    J Neurooncol 106:303-13. 2012
    ..Our results suggest that appropriate palliative systemic therapy after WBRT or GKS, and adequate palliative treatment via combined modalities are helpful for breast cancer patients, even after the detection of CNS metastases...
  52. ncbi Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 11:452. 2011
    ....
  53. ncbi Zinc-fingers and homeoboxes 1 (ZHX1) binds DNA methyltransferase (DNMT) 3B to enhance DNMT3B-mediated transcriptional repression
    Sung Hak Kim
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul, Republic of Korea
    Biochem Biophys Res Commun 355:318-23. 2007
    ..These results showed for the first the direct linkage between DNMT and zinc-fingers homeoboxes protein, leading to enhanced gene silencing by DNMT3B...
  54. ncbi Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer
    Myung Deok Seo
    Department of Internal Medicine, Cheju National University Hospital, Jeju, Republic of Korea
    Jpn J Clin Oncol 38:589-95. 2008
    ..Factors to select patients who may benefit from salvage chemotherapy was also analysed...
  55. ncbi High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer
    Jiyoung Rhee
    Department of Internal Medicine, Seoul National University Hospital, 101 Daehang ro, Jongno gu, Seoul, Korea
    Breast Cancer Res Treat 125:107-14. 2011
    ..These data suggest that TGF-α plays a role in resistance to lapatinib and capecitabine therapy among HER2-positive breast cancer...
  56. ncbi Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer
    Hyun Jin Nam
    Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
    Cancer Lett 302:155-65. 2011
    ..Therefore, HM781-36B may be useful for the treatment of HER2 amplified gastric cancer alone or in combination with chemotherapeutic agents...
  57. ncbi Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI
    Hyeon Gyu Yi
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
    Lung Cancer 65:80-4. 2009
    ..Two patients showed responses to higher than standard dose of gefitinib. The median overall survival was not reached. In conclusion, EGFR TKIs are effective in the treatment of LM from NSCLC when patients were selected properly...
  58. ncbi Age <40Years is an independent prognostic factor predicting inferior overall survival in patients treated with breast conservative therapy
    Kyubo Kim
    Departments of Radiation Oncology Surgery Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Breast J 17:75-8. 2011
    ..There was also a trend for inferior DMFS and OS in younger patients. Age at diagnosis should be considered for individualized patient management...
  59. ncbi Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
    Young Kwang Yoon
    Cancer Research Institute, Seoul National University College of Medicine, Korea
    Mol Cancer Ther 8:2526-36. 2009
    ..Our results provide the basis for a rational combination strategy against human EGFR WT gastric cancers, predicated on the understanding of cross-talk between the MEK and EGFR pathways...
  60. ncbi Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins
    Kyung Hun Lee
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    Cancer Sci 102:1388-95. 2011
    ....
  61. ncbi Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity
    Kyu Hyoung Lim
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    Jpn J Clin Oncol 40:112-8. 2010
    ..The aim of this study was to compare the clinical features and prognosis between triple-negative metaplastic carcinoma (TNMC) and non-triple-negative metaplastic carcinoma (NTNMC)...
  62. ncbi Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression
    Hyeong Gon Moon
    Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, Korea
    Breast Cancer Res Treat 134:1133-40. 2012
    ..Our observation generates the hypothesis that the optimal duration of NST can be tailored to the molecular phenotypes of tumors...
  63. ncbi Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers
    Jiyeon Yun
    Cancer Research Institute, Seoul National University College of Medicine, South Korea
    Lab Invest 92:1033-44. 2012
    ..Taken together, the results of our study showed for the first time that EREG is epigenetically silenced in gastric cancer cells by aberrant DNA methylation and histone modification...
  64. ncbi Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: a retrospective study
    Jiyoung Rhee
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    J Gastroenterol Hepatol 25:1537-42. 2010
    ..We evaluated the clinicopathologic features and clinical outcomes of this population...
  65. ncbi Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody
    Jun Gyu Kim
    Cancer Research Institute, Seoul National University, Seoul, South Korea
    PLoS ONE 7:e33322. 2012
    ..However, recent clinical trials showed that anti-IGF1R antibody and chemotherapy are not effective for treating lung cancer...
  66. ncbi Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells
    Young Kwang Yoon
    Cancer Research Institute, Seoul National University College of Medicine, South Korea
    Cancer Lett 316:77-84. 2012
    ..Our study provides a mechanism of differential response to MEK inhibition in KRAS mutant cancer...
  67. ncbi Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 7:203. 2007
    ..The purpose of this study was to identify the clinical significance of potential predictive and prognostic factors in breast cancer patients treated by neoadjuvant chemotherapy...
  68. ncbi Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study
    Kyu Hyoung Lim
    Departments of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    BMC Cancer 9:345. 2009
    ....
  69. ncbi Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study
    Dong Yeop Shin
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehagro, Chongno Gu, Seoul 110 744, Korea
    Cancer Chemother Pharmacol 68:165-75. 2011
    ..We conducted this study to investigate the clinical implication of SUVmax on (18)F FDG-PET as a prognostic factor in patients with HCC, especially in the metastatic setting...
  70. ncbi Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul, 110 744, Korea
    J Cancer Res Clin Oncol 137:1301-8. 2011
    ..The aim of this study was to combine clinical pathologic variables that are associated with pathologic completer response (pCR) and relapse-free survival (RFS) after neoadjuvant chemotherapy into prediction nomograms...
  71. ncbi Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy
    Bhumsuk Keam
    Department of Internal Medicine, Seoul National University College of Medicine, Chongno Gu, Seoul, Republic of Korea
    Breast Cancer Res Treat 116:153-60. 2009
    ..The purpose of this study was to identify the clinical significance of the involved nodal ratios in patients with stage II/III breast cancer treated with neoadjuvant chemotherapy...
  72. ncbi Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy
    Jin Won Kim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 110 744, South Korea
    Support Care Cancer 20:395-403. 2012
    ..The study aims to determine whether or not oral mucositis (OM) during active chemotherapy in patients with solid tumors is representative of the patient's quality of life (QOL) and the suffering from adverse effects...
  73. ncbi Role of adjuvant chemoradiotherapy for ampulla of Vater cancer
    Kyubo Kim
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Int J Radiat Oncol Biol Phys 75:436-41. 2009
    ..To evaluate the role of adjuvant chemoradiotherapy for ampulla of Vater cancer...
  74. ncbi Does adjuvant radiotherapy suppress liver regeneration after partial hepatectomy?
    Jin Hwa Choi
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
    Int J Radiat Oncol Biol Phys 74:67-72. 2009
    ..To analyze the influence of the adjuvant radiotherapy (RT) on the liver regeneration and liver function after partial hepatectomy (PH)...
  75. ncbi Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma
    Su Jung Kim
    Department of 1nternal Medicine, Seoul National University Hospital, Seoul 110 744, Republic of Korea
    Anticancer Res 30:5245-50. 2010
    ..Based on its potent inhibition of dihydropyrimidine dehydrogenase (DPD), S-1 is expected to be more active than other flouropyrimidines against tumors with higher DPD activity, such as hepatocellular carcinoma (HCC)...
  76. ncbi The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
    Jiyoung Rhee
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    BMC Cancer 8:307. 2008
    ..We investigated the clinicopathologic characteristics and prognostic indicators of lymph node-negative TN breast cancer...
  77. ncbi A-kinase anchoring protein 12 regulates the completion of cytokinesis
    Moon Chang Choi
    National Research Laboratory for Cancer Epigenetics, Cancer Research Institute, Seoul, Republic of Korea
    Biochem Biophys Res Commun 373:85-9. 2008
    ..Our findings implicate AKAP12 in the regulation of cytokinesis progression, and suggest a novel role for AKAP12 tumor suppressor...
  78. ncbi Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2
    Hwang Phill Kim
    Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
    PLoS ONE 4:e5933. 2009
    ..However, the molecular mechanism underlying the downregulation of TS has yet to be clearly elucidated...
  79. ncbi Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer
    Hye Jin Kim
    Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Republic of Korea
    Acta Oncol 48:385-90. 2009
    ..Therefore, this study was performed to determine the incidence of CEA and CA19-9 surges and their implications on the clinical outcome in MRGC patients...
  80. ncbi Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment
    Sae Won Han
    Department of Internal Medicine, Seoul National University Hospital, Republic of Korea
    Lung Cancer 61:30-4. 2008
    ..These data indicate for the first time that MEC of lung is another potential target of EGFR inhibitor, and more extended clinical investigation is warranted...
  81. ncbi The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma
    Hyeyoung Kim
    Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, 28 Yongon Dong, Chongno Gu, Seoul 100 744, Korea
    Breast Cancer Res Treat 126:637-41. 2011
    ..Chest CT, however, upstaged 6.0% of stage III patients to stage IV...
  82. ncbi Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less
    Ji Hyun Kwon
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
    BMC Cancer 10:557. 2010
    ..Whether a systemic adjuvant treatment is needed is an area of controversy in patients with node-negative early breast cancer with tumor size of ≤1 cm, including T1mic...
  83. ncbi Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer
    Do Youn Oh
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Youngon Dong, Chongno Gu, Seoul 110 744, Korea
    Jpn J Clin Oncol 35:380-5. 2005
    ..Our objective was to verify the efficacy and safety of "docetaxel + 5-fluorouracil + cisplatin" 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer...
  84. ncbi VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib
    Youngil Koh
    Department of Internal Medicine, Seoul National University Hospital, Korea
    Diagn Mol Pathol 20:143-7. 2011
    ..However, the genotype did not affect either response rate or the PFS of sunitinib. In conclusion, expressions of VEGF, PDGFR, and CD34 may have predictive value in sunitinib treatments...
  85. ncbi Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization
    Seock Ah Im
    Department of Internal Medicine, Cancer Research Institute, Seoul, Republic of Korea
    Diagn Mol Pathol 20:94-100. 2011
    ..2% vs. 43.3%, respectively; P=0.086). These findings suggest that further investigations of adjuvant therapy with HER2-targeted therapy for advanced GC are warranted...
  86. ncbi Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer
    Jin Hyun Park
    Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, 101 Daehang ro, Jongno gu, Seoul, 110 744, Republic of Korea
    Cancer Chemother Pharmacol 68:1045-55. 2011
    ..We also aimed to determine the relationship between molecular markers and clinical outcomes of cetuximab-containing chemotherapy...
  87. ncbi Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer
    Keun Wook Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    J Korean Med Sci 22:S115-21. 2007
    ..However, relatively short TTP of this regimen warrants the development of more effective paclitaxel-based regimens other than combination with cisplatin in these patients as second-line therapies...
  88. ncbi A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer
    Sook Ryun Park
    Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul 110-744, Korea
    Oncol Rep 12:1059-64. 2004
    ..In conclusion, the combination of Genexol and cisplatin was found to be an active and relatively well-tolerated regimen for the treatment of advanced gastric carcinoma...
  89. ncbi Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer
    Keun-Wook Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Chongno-gu, Seoul 110-744, Republic of Korea
    Jpn J Clin Oncol 35:720-6. 2005
    ..This regimen seems to have comparable efficacy to previously reported higher-dose paclitaxel plus cisplatin-containing regimens and fewer toxicities...
  90. ncbi Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer
    Jee Hyun Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
    J Korean Med Sci 20:806-10. 2005
    ..2%) and vomiting (1.0%). In conclusion, the mini-FOLFOX-4 regimen was found to be well tolerated with acceptable toxicity, and to provide a benefit for elderly patients with colorectal cancer...
  91. ncbi Individualized tumor response testing for prediction of response to Paclitaxel and Cisplatin chemotherapy in patients with advanced gastric cancer
    Jee Hyun Kim
    Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
    J Korean Med Sci 25:684-90. 2010
    ..ATP-CRA could predict clinical response to paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric cancer patients. Our study supports the use of ATP-CRA in further validation studies...
  92. ncbi Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer
    Kyung-Hun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Chongno-gu, Seoul, 110-744, South Korea
    Jpn J Clin Oncol 36:344-50. 2006
    ..Our results also suggest that it may be undesirable to use gemcitabine in patients with tumors not expressing p-Erk...
  93. ncbi Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies
    Do-Youn Oh
    Seoul Municipal Boramae Hospital and Department of Internal MEdicine, Seoul National University College of Medicine, Chongno-gu, Seoul, Republic of Korea
    Cancer 100:1961-6. 2004
    ..To resolve controversies regarding the role of the physician in end-of-life decision-making, the values of physicians, patients, and family members should be considered in the final decision-making process...
  94. ncbi Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives
    J W Kim
    Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
    Br J Cancer 99:1593-9. 2008
    ..This information would be very helpful for investigators to properly conduct CTs in eastern cancer patients...
  95. ncbi Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy
    Jae Jin Lee
    Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    Jpn J Clin Oncol 34:400-4. 2004
    ..CONCLUSION: The response rate to capecitabine was low in metastatic colorectal cancers that were refractory to 5-FU/LV-containing chemotherapy. However, disease stabilization was seen in a significant number of patients...
  96. ncbi Discrepancies in performance status scores as determined by cancer patients and oncologists: are they influenced by depression?
    Hong Jin Jeon
    Department of Psychiatry and Behavioral Science, Seoul National University College of Medicine, Institute of Human Behavioral Medicine, Medical Research Center, Seoul National University, 28 Yeongeon dong, Chongno Gu, Seoul 110 744, South Korea
    Gen Hosp Psychiatry 29:555-61. 2007
    ..In previous research studies, performance status as determined by cancer patients themselves frequently did not agree with that determined by their oncologists. However, only a few studies have evaluated the reasons for this discrepancy...
  97. ncbi Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin
    Sun Young Kim
    Department of Internal Medicine, Seoul National University College of Medicine, Chongro Gu, Seoul 110 799, Korea
    Int J Oncol 32:89-95. 2008
    ..These results suggest that trastuzumab combined with chemotherapeutic agents can be active against gastric cancer with HER2 amplification...
  98. ncbi Weight changes after adjuvant treatment in Korean women with early breast cancer
    Hye Suk Han
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 300 Gumi dong, Bundang gu, Seongnam, Gyeonggi, 463 707, Korea
    Breast Cancer Res Treat 114:147-53. 2009
    ..However, most data are limited to Western women. We evaluated weight changes after adjuvant treatment in Korean women with early breast cancer...
  99. ncbi Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
    Jeeyun Lee
    Division of Hematology Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Kangnam Gu, Seoul, Korea
    Cancer Chemother Pharmacol 64:657-63. 2009
    ..This phase II trial evaluated the efficacy and toxicity profile of conventional FOLFIRI chemotherapy plus simvastatin in metastatic colorectal cancer patients...
  100. ncbi Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors
    Jung Hyun Park
    Laboratory for Cancer Epigenetics and Experimental Therapeutics, Cancer Research Institute, Seoul, Republic of Korea
    Biochem Biophys Res Commun 368:318-22. 2008
    ..Overall, these results indicate that HDAC6 and HDAC10 play important roles in Hsp-mediated VEGFR regulation...
  101. ncbi Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma
    Sung Hoon Sim
    Department of Internal Medicine, Seoul National University Hospital, Republic of Korea
    Lung Cancer 65:204-7. 2009
    ..Novel treatment approaches such as the use of irreversible TKIs or anti-cMET agents for those patients are warranted...